COVID-19: Wockhardt in discussions with vaccine developers to offer drug substance
According to the company, the UK government has reserved one fill and finish production line at Wockhardt UK for its exclusive use for 18 months in order to guarantee the supply of vaccines required to fight against COVID-19. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2020 Category: Pharmaceuticals Source Type: news

Divi's Lab earmarks Rs 1,500 cr to set up manufacturing facility in Andhra Pradesh
Drugmaker Divi's Laboratories on Tuesday said it has earmarked Rs 1,500 crore to set up a new manufacturing facility in Andhra Pradesh. The work on the manufacturing plant would commence from December 7, Divi's Laboratories said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2020 Category: Pharmaceuticals Source Type: news

BioNTech, Pfizer ask Europe to quickly approve virus vaccine
The German pharmaceutical company BioNTech and its U.S. partner Pfizer say they have submitted an application for speeded-up, conditional approval of their coronavirus vaccine with the European Medicines Agency. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2020 Category: Pharmaceuticals Source Type: news

Initial findings into 'adverse event' did not necessitate halting of trials: Govt
A 40-year-old man who was a volunteer in the third phase of the ''Covidshield'' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions. He has sought Rs 5 crore compensation in a legal notice to Serum Institute and others, besides seeking a halt to the trial. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca partner sticks with two full dose regimen in Covid trials in India
The British drugmaker has said its Covid-19 vaccine could be up to 90% effective if administered as a half dose followed by a full dose, but some scientists have questioned the robustness of that result because only a few thousand people were given that regimen in late-stage UK trials. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 1, 2020 Category: Pharmaceuticals Source Type: news

Mankind Pharma announces Mohanlal as corporate brand ambassador
Rajeev Juneja, CEO of Mankind Pharma, said the pharma company has been recognising the real heroes of society and it really wanted to associate with a familiar face who is a changemaker. "Mohanlal is a real fit as the corporate brand ambassador for Mankind Pharma. We believe in giving back to the society through our CSR activities and thereby lending a helping hand to the ones in need." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 30, 2020 Category: Pharmaceuticals Source Type: news

Auto-disable syringes are the best option to prevent reuse: HS Ratti, epidemiologist
"Companies making these syringes have large capacities. They should be able to supply the desired quantity. There are regular training programs conducted across states to train medical staff in areas of safe injection practices. Well-trained nurses and paramedics should be able to administer injections using AD syringes. The process is almost the same." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 30, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute rejects charges levelled by vaccine trial participant, will seek Rs 100 crore in damages
A 40-year-old man who took part in the 'Covidshield' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions and has sought Rs 5 crore compensation in a legal notice to Serum Institute and others, besides seeking a halt to the trial. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 29, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute rejects charges levelled by vaccine trial participant, threatens to seek damages
A 40-year-old man who took part in the 'Covidshield' vaccine trial in Chennai has alleged serious side effects, including a virtual neurological breakdown and impairment of cognitive functions and has sought Rs 5 crore compensation in a legal notice to Serum Institute and others, besides seeking a halt to the trial. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 29, 2020 Category: Pharmaceuticals Source Type: news

Pharma hiring to remain conservative despite pace in vaccine development: Study
The top 25 pharma brands by size have a total active job openings count of about 4,500 jobs globally and only 6% of these active openings are currently open in India, according to the study on human capital and job information. The data collected for the study is from top job boards, company career pages, and official company pages on social media. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

Gujarat: PM Modi reviews vaccine development at Zydus Cadila facility
After his arrival at Ahmedabad airport from Delhi shortly after 9 am, Modi flew to the Zydus Cadila plant and held discussions with the promoters and executives of the company, an official said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

PM's presence to motivate company in quest to bridge unmet healthcare needs: Zydus Cadila
The Zydus family comprising 25,000 Zydans stands committed to the 'Aatmanirbhar Bharat' mission and offering the nation safe and efficacious vaccines, therapeutics and diagnostics to fight COVID-19, said the company. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

PM Modi visits Bharat Biotech's vaccine manufacturing facility in Hyderabad
Covaxin, being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology, is now undergoing phase-3 trials. The Phase-3 trials involve 26,000 volunteers across India, conducted in partnership with ICMR. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

SII to seek emergency use authorisation for AstraZeneca Covid vaccine in 2 weeks: Poonawalla
Adar Poonawalla, Founder and CEO, SII said on Saturday that SII is in the process of submitting the data for the clinical trials to the DCGI and will seek emergency use authorisation. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

Centre may purchase 300-400 million Covishield doses by July 2021: Adar Poonawalla
SII has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine candidate 'Covidshield'. "As of now we don't have anything in writing of how many doses the Government of India would purchase, but the indication is three to four hundred million doses by July 2021," Poonawalla said in a media interaction. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

COVID vaccine will be distributed initially in India; amazed at how much PM Modi knew: Adar Poonawalla
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine
Dr Reddy's Laboratories on Saturday said it has inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

The curious case of AstraZeneca-Oxford vaccine
The company announced that in a small subgroup of the trial participants the vaccine showed better efficacy when administered a half dose first and a full dose after a month. This announcement triggered a series of questions on the company ’s trial protocol. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 28, 2020 Category: Pharmaceuticals Source Type: news

PLI schemes for bulk drugs, medical devices get encouraging response: Govt
The PLI scheme for Bulk Drugs has received 247 registrations across all four categories of products out of which a maximum of 136 applicants will be selected under the scheme, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 27, 2020 Category: Pharmaceuticals Source Type: news

Zydus Cadila to apply for Phase-3 trials in December, hopes to launch vaccine by March
The Ahmedabad-based drug maker will submit the results of its phase-2 trials next week, which "will ascertain the safety, dose and efficacy of the potential vaccine", said the person who requested not to be identified. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 27, 2020 Category: Pharmaceuticals Source Type: news

Russia agrees to produce coronavirus vaccine Sputnik V in India, set to work with Hetero
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 27, 2020 Category: Pharmaceuticals Source Type: news

PM Narendra Modi to review Covid vaccine work in Ahmedabad, Pune and Hyderabad
The drug maker had earlier announced that the phase-I clinical trial of its COVID-19 vaccine candidate, ZyCoV-D, has been completed and it has commenced phase-II clinical trials from August. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 27, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca inks pact with Research Society for Study of Diabetes in India
As a key facet of this association, the company has unveiled a three-year patient awareness programme, 'Beyond Sugar', developed to benefit over 1 crore people living with diabetes across the country, AstraZeneca India said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca-Oxford vaccine safe, Indian trials progressing smoothly: Serum Institute
Vaccine major Serum Institute of India on Thursday said the Covid-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly with strict adherence to all protocols. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

Questions over AstraZeneca's COVID-19 vaccine data risk delaying approval
Several scientists have raised doubts about the robustness of results showing the shot was 90% effective in a sub-group of trial participants who, by error initially, received a half dose followed by a full dose. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

Infectious diseases' drug research back on the radar of Big Pharma
Companies such as Gilead, Eli Lilly and Regeneron have worked on novel treatments, either from their own labs or by reviving molecules that had been abandoned during other epidemics. For example, Gilead ’s Remdesivir was originally tried as a cure for Ebola. Companies such as Eli Lilly and Regeneron have revived the field of antibody therapy that has become a key foundation for Covid-19 treatments. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

There are over 200 COVID-19 vaccines currently in development, here's what you need to know
A breakdown of everything we know about the most likely vaccine candidates, the countries that have first access and who's manufacturing for whom and where. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

After admitting mistake, AstraZeneca faces difficult questions about its coronavirus vaccine
Since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine ’s apparently spectacular efficacy will hold up under additional testing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

Questions remain even as highly promising COVID-19 vaccines are on the cusp of release
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 26, 2020 Category: Pharmaceuticals Source Type: news

Making functional human tissues is just a start for Pandorum Tech
​​Pandorum is backed by the Indian Angel Network, Flipkart cofounder Binny Bansal, Hero Group promoter Sunil Munjal and the Biotechnology Industry Research Assistance Council. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Alembic Pharma's JV Aleor Dermaceuticals gets tentative nod from USFDA for testosterone gel
Aleor Dermaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Testosterone Gel, 1.62 per cent (20.25 mg/1.25 gm actuation), Alembic Pharmaceuticals said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Oxford vaccine: Kiran Mazumdar-Shaw seeks quick regulatory processing after UK nod
She cited reports according to which the UK's medicines and healthcare products regulatory agency (MHRA) is likely to grant EUA by mid December. A couple of weeks later, she said, the drugs controller general of India (DCGI) could allow it for emergency use in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

When and how will COVID-19 vaccines become available?
If regulators approve any of the vaccines in coming weeks, the companies have said distribution could begin almost immediately with governments around the world to decide who gets them and in what order. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

All you need to know about Russia's Sputnik V coronavirus vaccine which is easier to store
In a statement on Tuesday, the vaccine's developers said preliminary data after trials involving thousands of volunteers showed "an efficacy of the vaccine above 95 percent" after a second dose. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Indian vaccine makers - Serum and Gennova - set to host over 20 foreign diplomats this week
The move comes as the Indian government thinks that it has sufficient doses of vaccine for its population and can also supply to other nations that might be left out in the Covid-19 vaccine race as countries in Europe and US secure their own doses, said an official. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

What we know about AstraZeneca-Oxford's head-scratching Covid vaccine results
AstraZeneca's vaccone announcement came on the heels of stunning reports from Moderna, as well as Pfizer and BioNTech. But AstraZeneca ’s news was murkier, leaving many experts wanting to see more data before passing final judgment on how effective the vaccine may turn out to be. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2020 Category: Pharmaceuticals Source Type: news

There will be a price to pay for making vaccines too expensive
It is in everyone ’s interest — including the residents of the world’s poorest countries, who depend upon innovation in the world’s richest nations to improve their lives — to head off this disgruntlement before it has a chance to gather political momentum. Some corporations do recognize this. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2020 Category: Pharmaceuticals Source Type: news

Biological E to start phase-III trials by January, license vaccine by summer
Disclosing this in Hyderabad on Monday, managing director Mahima Datla said the company is currently evaluating four different formulations depending on different antigen strengths in the phase I-II combined studies. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2020 Category: Pharmaceuticals Source Type: news

Covid-19: Decades of work, and half a dose of fortune, drove Oxford vaccine success
While skill and hard work drove development, AstraZeneca said it was a minor mistake that made the team realise how they could significantly boost the shot's success rate, to as much as 90% from around 60%: by administering a half dose, followed by a full dose a month later. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca must prove claim to cheapest COVID-19 vaccine: MSF
The British firm said on Monday its COVID-19 vaccine was 70% effective in pivotal trials and could be up to 90% effective, giving the world's fight against the global pandemic a third new weapon that can be cheaper to make, easier to distribute and faster to scale-up than rivals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 24, 2020 Category: Pharmaceuticals Source Type: news

How the vaccine developed by Oxford University stacks up against Pfizer and Moderna
AstraZeneca said November 23 that late-stage trials showed its coronavirus vaccine was up to 90% effective, giving public health officials hope they may soon have access to a vaccine that is easier to distribute than some of its rivals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Serum Institute to focus on supplying COVID-19 vaccine to India first
Poonawalla's comments came shortly after AstraZeneca said on Monday its vaccine could be around 90% effective, giving the world's fight against the pandemic a new weapon, cheaper to make, easier to distribute and faster to scale up than rivals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Dosing error turns into lucky punch for AstraZeneca and Oxford
The British drugmaker said on Monday that the vaccine could be around 90% effective, when administered as a half dose followed by a full dose a month later, citing data from late-stage trials in Britain and Brazil. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19: Govt may get Oxford shots in Jan-Feb, at 50% of MRP
India is likely to get the first lot of anti-Covid shots in late January-early February. This will be possible as India plans to give Serum Institute of India emergency use approval for the Oxford-AstraZeneca vaccine candidate soon after it gets similar approval in the UK. The government, which will make bulk purchases, has also negotiated a better price — almost half that of the likely MRP of Rs 500-600 for the two-shot vaccine. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

COVID-19: Favipiravir shows hope in Mumbai trial
While the WHO last week recommended that antiviral remdesivir not be used for severely ill Covid-19 patients, Mumbai doctors published the first scientific study showing another antiviral, favipiravir, reduced the "cure time" in mild cases. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Strides Pharma Science gets USFDA nod for Prednisone tablets
Strides Pharma Science Ltd on Monday said it has received approval from the US health regulator for its generic version of Prednisone tablets, prescribed for a variety of conditions, including allergies, respiratory illness and arthritis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca/Oxford say Covid vaccine shows 70% efficacy, can be 90% effective
"This vaccine's efficacy and safety confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency," AstraZeneca chief executive Pascal Soriot said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Study shows Favipiravir provides multiple benefits in COVID-19 treatment: Glenmark
The Phase 3 study with Favipiravir, sold under the brand name FabiFlu, by the company was conducted in 150 patients, it added. Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy, Glenmark said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19 vaccine: Oxford trials show 70 per cent efficacy
(Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca will have 200 million COVID vaccine doses by year-end
Its operations executive Pam Cheng told a briefing that there would be 20 million doses in Britain by the end of the year, with 70 million doses for the UK by the end of Q1 2021. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 23, 2020 Category: Pharmaceuticals Source Type: news